EGFR (V948R)

EGFR · Variant type: point · HGVS: p.V948R

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Neratinib	99.5%	0.5%	93.18
2	Defactinib	99.4%	0.6%	92.68
3	Mobocertinib	98.4%	1.6%	97.22
4	Canertinib	98.2%	1.8%	96.49
5	Erlotinib	97.3%	2.7%	99.75
6	Zanubrutinib	97.2%	2.8%	98.24
7	Lazertinib	96.6%	3.4%	97.47
8	Vandetanib	96.5%	3.5%	95.74
9	Pirtobrutinib	92.9%	7.1%	99.49
10	Pralsetinib	90.4%	9.6%	93.43
11	Avapritinib	81.9%	18.1%	97.73
12	Gilteritinib	74.5%	25.5%	88.97
13	Pacritinib	69.0%	31.0%	88.64
14	Tivozanib	41.9%	58.1%	92.42
15	Alpelisib	39.8%	60.2%	97.22
16	Acalabrutinib	36.3%	63.7%	99.50
17	Deucravacitinib	33.9%	66.1%	98.99
18	Pemigatinib	22.7%	77.3%	98.23
19	Capmatinib	21.8%	78.2%	99.75
20	Fedratinib	18.6%	81.4%	96.21
21	Mitapivat	17.0%	83.0%	100.00
22	Paxalisib	13.0%	87.0%	99.75
23	Pexidartinib	12.8%	87.2%	99.49
24	Sunitinib	12.4%	87.6%	91.73
25	Quizartinib	12.1%	87.9%	99.50

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Neratinib	99.5%	100.0%	-0.5%
Defactinib	99.4%	94.6%	+4.8%
Mobocertinib	98.4%	100.0%	-1.6%
Canertinib	98.2%	98.4%	-0.2%
Erlotinib	97.3%	99.4%	-2.2%
Zanubrutinib	97.2%	88.2%	+9.0%
Lazertinib	96.6%	100.0%	-3.4%
Vandetanib	96.5%	99.3%	-2.8%
Pirtobrutinib	92.9%	—	—
Pralsetinib	90.4%	99.1%	-8.7%
Avapritinib	81.9%	—	—
Gilteritinib	74.5%	91.0%	-16.5%
Pacritinib	69.0%	—	—
Tivozanib	41.9%	—	—
Alpelisib	39.8%	—	—
Acalabrutinib	36.3%	—	—
Deucravacitinib	33.9%	—	—
Pemigatinib	22.7%	—	—
Capmatinib	21.8%	—	—
Fedratinib	18.6%	—	—
Mitapivat	17.0%	—	—
Paxalisib	13.0%	—	—
Pexidartinib	12.8%	—	—
Sunitinib	12.4%	—	—
Quizartinib	12.1%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.0ms